WashU Expert: Trump’s new NAFTA won’t lower domestic drug prices
President Donald Trump has touted his new United States-Mexico-Canada Agreement as a way to boost the American economy. It may not, however, have any impact on one of his other campaign promises: reducing prescription costs for U.S. consumers, says a drug pricing expert at Washington University in St. Louis.
‘The process by which drugs are discovered and developed will be fundamentally different in the future’
Over the past several decades, Michael Kinch of Washington University in St. Louis says, the pharmaceutical industry has managed to dismantle itself. In a provocative series of articles and interviews, Kinch, the director of the Center for Research Innovation in Businessat the university, has been describing the history of this dismantling and its implications for the future of medicine.